Posted by Michael Wonder on 05 Mar 2025
Sparsentan for the treatment of patients with primary IgA nephropathy
4 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of sparsentan in the NHS in England.
For the time being, sparsentan is not recommended for the treatment of adults with primary immunoglobulin A nephropathy with a urine protein excretion of 1.0 g/day or more, or a urine protein to creatinine ratio of 0.75 g/g or more.
